FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519469881> ?p ?o ?g. }

• W2519469881 endingPage "3362" @default.
• W2519469881 startingPage "3354" @default.
• W2519469881 abstract "Therapeutic antibodies against programmed cell death receptor 1 (PD-1) are considered front-line therapy in metastatic melanoma. The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described.A multi-institutional, retrospective cohort analysis identified adults with advanced acral and mucosal melanoma who received treatment with nivolumab or pembrolizumab as standard clinical practice through expanded access programs or published prospective trials. Objective responses were determined using investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival and overall survival were assessed using the Kaplan-Meier method.Sixty individuals were identified, including 25 (42%) with acral melanoma and 35 (58%) with mucosal melanoma. Fifty-one patients (85%) had received previous therapy, including 77% who had previously received ipilimumab. Forty patients (67%) received pembrolizumab at a dose of 2 mg/kg or 10 mg/kg, and 20 (33%) received nivolumab at a doses ranging from 0.3 to 10 mg/kg every 2 to 3 weeks. The objective response rate was 32% (95% confidence interval, 15%-54%) in patients with acral melanoma and 23% (95% confidence interval, 10%-40%) in those with mucosal melanoma. After a median follow-up of 20 months in the acral melanoma group and 10.6 months in the mucosal melanoma group, the median progression-free survival was 4.1 months and 3.9 months, respectively. Only 2 patients (3%) discontinued treatment because of toxicity.Response rates to PD-1 blockade in patients with acral and mucosal melanomas were comparable to the published rates in patients with cutaneous melanoma and support the routine use of PD-1 blockade in clinical practice. Further investigation is needed to identify the mechanisms of response and resistance to therapy in these subtypes. Cancer 2016;122:3354-3362. © 2016 American Cancer Society." @default.
• W2519469881 created "2016-09-23" @default.
• W2519469881 creator A5008479799 @default.
• W2519469881 creator A5011325668 @default.
• W2519469881 creator A5025067315 @default.
• W2519469881 creator A5025872938 @default.
• W2519469881 creator A5031721461 @default.
• W2519469881 creator A5035762857 @default.
• W2519469881 creator A5040291209 @default.
• W2519469881 creator A5041066193 @default.
• W2519469881 creator A5042621368 @default.
• W2519469881 creator A5049243227 @default.
• W2519469881 creator A5052526230 @default.
• W2519469881 creator A5054656505 @default.
• W2519469881 creator A5058950476 @default.
• W2519469881 creator A5063337705 @default.
• W2519469881 creator A5072582710 @default.
• W2519469881 creator A5073798429 @default.
• W2519469881 creator A5083745558 @default.
• W2519469881 creator A5088042471 @default.
• W2519469881 creator A5088805339 @default.
• W2519469881 creator A5090769354 @default.
• W2519469881 date "2016-08-17" @default.
• W2519469881 modified "2023-10-18" @default.
• W2519469881 title "The efficacy of anti-PD-1 agents in acral and mucosal melanoma" @default.
• W2519469881 cites W129007473 @default.
• W2519469881 cites W1498931318 @default.
• W2519469881 cites W1508084728 @default.
• W2519469881 cites W1545177819 @default.
• W2519469881 cites W1809627231 @default.
• W2519469881 cites W1940241680 @default.
• W2519469881 cites W1970051943 @default.
• W2519469881 cites W1980569791 @default.
• W2519469881 cites W1989121777 @default.
• W2519469881 cites W1990675339 @default.
• W2519469881 cites W1994347920 @default.
• W2519469881 cites W2021419048 @default.
• W2519469881 cites W2039123767 @default.
• W2519469881 cites W2049553585 @default.
• W2519469881 cites W2049620463 @default.
• W2519469881 cites W2086862385 @default.
• W2519469881 cites W2096119920 @default.
• W2519469881 cites W2098835477 @default.
• W2519469881 cites W2104885590 @default.
• W2519469881 cites W2107429737 @default.
• W2519469881 cites W2107484016 @default.
• W2519469881 cites W2112121482 @default.
• W2519469881 cites W2118919757 @default.
• W2519469881 cites W2118982164 @default.
• W2519469881 cites W2124427232 @default.
• W2519469881 cites W2128035403 @default.
• W2519469881 cites W2128758225 @default.
• W2519469881 cites W2143163879 @default.
• W2519469881 cites W2145872748 @default.
• W2519469881 cites W2152897456 @default.
• W2519469881 cites W2156266404 @default.
• W2519469881 cites W2160834915 @default.
• W2519469881 cites W2161890731 @default.
• W2519469881 cites W2166662937 @default.
• W2519469881 cites W2168198731 @default.
• W2519469881 cites W2170552969 @default.
• W2519469881 cites W2408787182 @default.
• W2519469881 cites W2515516401 @default.
• W2519469881 cites W2560367415 @default.
• W2519469881 cites W2572174216 @default.
• W2519469881 doi "https://doi.org/10.1002/cncr.30259" @default.
• W2519469881 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5134420" @default.
• W2519469881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27533633" @default.
• W2519469881 hasPublicationYear "2016" @default.
• W2519469881 type Work @default.
• W2519469881 sameAs 2519469881 @default.
• W2519469881 citedByCount "222" @default.
• W2519469881 countsByYear W25194698812016 @default.
• W2519469881 countsByYear W25194698812017 @default.
• W2519469881 countsByYear W25194698812018 @default.
• W2519469881 countsByYear W25194698812019 @default.
• W2519469881 countsByYear W25194698812020 @default.
• W2519469881 countsByYear W25194698812021 @default.
• W2519469881 countsByYear W25194698812022 @default.
• W2519469881 countsByYear W25194698812023 @default.
• W2519469881 crossrefType "journal-article" @default.
• W2519469881 hasAuthorship W2519469881A5008479799 @default.
• W2519469881 hasAuthorship W2519469881A5011325668 @default.
• W2519469881 hasAuthorship W2519469881A5025067315 @default.
• W2519469881 hasAuthorship W2519469881A5025872938 @default.
• W2519469881 hasAuthorship W2519469881A5031721461 @default.
• W2519469881 hasAuthorship W2519469881A5035762857 @default.
• W2519469881 hasAuthorship W2519469881A5040291209 @default.
• W2519469881 hasAuthorship W2519469881A5041066193 @default.
• W2519469881 hasAuthorship W2519469881A5042621368 @default.
• W2519469881 hasAuthorship W2519469881A5049243227 @default.
• W2519469881 hasAuthorship W2519469881A5052526230 @default.
• W2519469881 hasAuthorship W2519469881A5054656505 @default.
• W2519469881 hasAuthorship W2519469881A5058950476 @default.
• W2519469881 hasAuthorship W2519469881A5063337705 @default.
• W2519469881 hasAuthorship W2519469881A5072582710 @default.
• W2519469881 hasAuthorship W2519469881A5073798429 @default.
• W2519469881 hasAuthorship W2519469881A5083745558 @default.

• next